- In April 2023, Aurobindo Pharma Ltd., a prominent player in the global generics market, announced the expansion of its cardiovascular product line with an upgraded formulation of Lisinopril targeting improved patient compliance and shelf life. This strategic move demonstrates the company’s commitment to addressing the growing burden of cardiovascular diseases, particularly in emerging economies. The initiative also reinforces Aurobindo’s competitive positioning in the global Lisinopril market by aligning product innovation with evolving healthcare needs
- In March 2023, Teva Pharmaceutical Industries Ltd. launched a new generic version of Lisinopril-Hydrochlorothiazide tablets in the U.S. market. The launch enhances accessibility to cost-effective combination therapies for hypertension management, especially in underserved populations. This advancement underlines Teva’s strategic focus on expanding its generics portfolio and meeting high-demand therapeutic segments, thereby strengthening its foothold in the global Lisinopril space
- In March 2023, Pfizer Inc. announced results from a Phase IV real-world study comparing the effectiveness of Lisinopril against other ACE inhibitors in preventing secondary cardiovascular events among high-risk patients. The study showed a statistically significant improvement in patient outcomes with Lisinopril use, which is expected to influence clinical guidelines and prescribing patterns globally. This development underscores Pfizer’s role in generating evidence-based data to support optimal hypertension care
- In February 2023, Lupin Pharmaceuticals, Inc. received regulatory approval from the European Medicines Agency (EMA) for its Lisinopril oral solution, targeting pediatric and geriatric patients with swallowing difficulties. This marks a significant milestone in the company’s strategy to provide patient-centric dosage forms and expand its presence in niche formulations within the cardiovascular therapy space
- In January 2023, Cipla Inc. launched a digital patient support program across India focused on chronic disease management, including hypertension and heart failure. The program features educational content, medication reminders, and teleconsultation support for patients using Lisinopril. This initiative reflects Cipla’s commitment to enhancing therapy adherence and improving outcomes through digital innovation, further advancing the market penetration of Lisinopril in the Asia-Pacific region
